olivLaw · US equity research
Ceribell, Inc. CBLL
Electromedical & Electrotherapeutic Apparatus · SIC 3845 · Vertical: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Ceribell is a medical technology company that develops a portable point-of-care EEG system with AI-powered algorithms for detecting seizures and delirium in intensive care and emergency settings. In the second quarter of 2026 the company reported 33% revenue growth and raised its fiscal 2026 revenue guidance to a range of 114 to 117 million USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Ceribell, Inc. (CBLL) stock was 27.39 USD (−3.11% on the day), with market capitalisation 1.1 bn USD, beta 1.45, 52-week range 11.56–28.27 USD. Latest reported quarter (Q3 2026): revenue of 29.3 m USD (+29.9% YoY), net income of -21.4 m USD, diluted EPS -0.55 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 56.4
- strong (55–70)
- Bollinger (20, 2)
- 23.91 – 29.20
- in the upper half of the band · %B 0.66 · band width 19.9%
- SMA 50 / 200
- 25.13 / 20.86
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.81 / 0.82
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +10.2% | −2.0% | +12.2 pp | — |
| 3 months | +49.8% | −2.2% | +51.9 pp | — |
| 6 months | +35.9% | +4.3% | +31.7 pp | — |
| Year to date | +24.9% | +10.6% | +14.3 pp | — |
| 1 year | +150.8% | +10.5% | +140.4 pp | −2.6% |
| 3 years | unavailable | +73.7% | unavailable | −18.0% |
| 5 years | unavailable | +61.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.5 m | 20.5 m | 21.2 m | 22.6 m | 24.8 m | 26.5 m | 28.1 m | 29.3 m |
| Cost of revenue | 2.3 m | 2.5 m | 2.5 m | 2.6 m | 3.1 m | 3.4 m | 2.2 m | 3.0 m |
| Gross profit | 16.2 m | 18.0 m | 18.7 m | 19.9 m | 21.6 m | 23.1 m | 25.9 m | 26.3 m |
| Research & development | 3.9 m | 4.2 m | 4.9 m | 5.0 m | 5.1 m | 6.2 m | 6.7 m | 7.4 m |
| Operating income | -12.9 m | -14.2 m | -15.0 m | -14.6 m | -14.6 m | -20.7 m | -20.0 m | -20.5 m |
| Depreciation & amortisation | 364.0 k | 335.0 k | 200.0 k | 300.0 k | 291.0 k | 239.0 k | 200.0 k | 200.0 k |
| Interest expense | 499.0 k | 471.0 k | 477.0 k | 480.0 k | 462.0 k | 434.0 k | 438.0 k | 267.0 k |
| Pre-tax income | -12.6 m | -12.8 m | -13.6 m | -13.5 m | -13.5 m | -19.7 m | -19.3 m | -21.4 m |
| Income tax | — | — | 0 | 0 | 0 | — | 0 | 0 |
| Net income | -12.6 m | -12.8 m | -13.6 m | -13.5 m | -13.5 m | -19.7 m | -19.3 m | -21.4 m |
| Diluted EPS | -0.41 ≈ | -0.36 | -0.38 | -0.37 | -0.36 ≈ | -0.52 | -0.51 | -0.55 |
| Operating cash flow | -10.0 m | -11.4 m | -7.5 m ≈ | -11.1 m ≈ | -10.8 m | -19.3 m | -12.9 m ≈ | -13.1 m ≈ |
| Capex | 357.0 k | 148.0 k | 71.0 k ≈ | 369.0 k ≈ | 179.0 k | 125.0 k | 17.0 k ≈ | 100.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 45.2 m | 65.4 m | 89.1 m |
| Revenue YoY | unavailable | +44.7% | +36.1% |
| Net income | -29.5 m | -40.5 m | -53.4 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -5.56 | -3.39 | -1.46 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | -65.1% | -61.8% | -60.0% |
| Free cash flow | -30.1 m | -36.4 m | -41.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 40.5 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 155.3 m USD
- Total assets
- 195.8 m USD
- Debt / equity
- unavailable
- Current ratio
- 9.73x
- ROE
- -30.8%
- ROA
- -25.4%
- FCF margin
- -46.7%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 45.2 m | 65.4 m | 89.1 m | SEC (XBRL)· 24 Feb 2026verified |
| Cost of revenue | 7.1 m | 8.7 m | 10.8 m | SEC (XBRL)· 24 Feb 2026verified |
| Gross profit | 38.2 m | 56.8 m | 78.3 m | SEC (XBRL)· 24 Feb 2026verified |
| Research & development | 9.0 m | 13.6 m | 19.1 m | SEC (XBRL)· 24 Feb 2026verified |
| Operating income | -30.0 m | -39.7 m | -58.4 m | SEC (XBRL)· 24 Feb 2026verified |
| Depreciation & amortisation | 847.0 k | 1.1 m | 1.3 m | SEC (XBRL)· 24 Feb 2026verified |
| EBITDA | -29.2 m ≈ | -38.6 m ≈ | -57.1 m ≈ | SEC (XBRL)· 24 Feb 2026derived |
| Interest expense | 2.1 m | 2.0 m | 1.9 m | SEC (XBRL)· 24 Feb 2026verified |
| Pre-tax income | -29.5 m | -40.5 m | -53.4 m | SEC (XBRL)· 24 Feb 2026verified |
| Income tax | 11.0 k | 0 | 0 | SEC (XBRL)· 24 Feb 2026verified |
| Net income | -29.5 m | -40.5 m | -53.4 m | SEC (XBRL)· 24 Feb 2026verified |
| Diluted EPS | -5.56 | -3.39 | -1.46 | SEC (XBRL)· 24 Feb 2026verified |
| Weighted average diluted shares | 5.3 m | 11.9 m | 36.5 m | SEC (XBRL)· 24 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 34.5 m | 194.4 m | 40.5 m | SEC (XBRL)· 24 Feb 2026verified |
| Receivables | 8.0 m | 10.9 m | 15.1 m | SEC (XBRL)· 24 Feb 2026verified |
| Inventories | 5.9 m | 6.9 m | 7.3 m | SEC (XBRL)· 24 Feb 2026verified |
| Current assets | 52.0 m | 217.3 m | 186.7 m | SEC (XBRL)· 24 Feb 2026verified |
| Property, plant & equipment, net | 1.6 m | 2.3 m | 2.0 m | SEC (XBRL)· 24 Feb 2026verified |
| Total assets | 58.9 m | 225.4 m | 195.8 m | SEC (XBRL)· 24 Feb 2026verified |
| Accounts payable | 732.0 k | 1.1 m | 2.8 m | SEC (XBRL)· 24 Feb 2026verified |
| Current liabilities | 21.6 m | 13.0 m | 19.2 m | SEC (XBRL)· 24 Feb 2026verified |
| Total liabilities | 23.8 m | 34.2 m | 40.5 m | SEC (XBRL)· 24 Feb 2026verified |
| Equity | -112.3 m † | 191.2 m † | 155.3 m † | SEC (XBRL)· 24 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -29.2 m | -35.0 m | -40.8 m | SEC (XBRL)· 24 Feb 2026verified |
| Capex | 983.0 k | 1.3 m | 767.0 k | SEC (XBRL)· 24 Feb 2026verified |
| Free cash flow | -30.1 m ≈ | -36.4 m ≈ | -41.6 m ≈ | SEC (XBRL)· 24 Feb 2026derived |
| Investing cash flow | -1.8 m | -1.6 m | -118.1 m | SEC (XBRL)· 24 Feb 2026verified |
| Financing cash flow | -2.8 m | 196.5 m | 5.1 m | SEC (XBRL)· 24 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.1 bn USD
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -68.0% | 36 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -47.4x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 8.2x | 100 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -5.3% | 0 (on a fixed band) | 33% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial36/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
CeriBell, Inc. (CBLL). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 89.1 m USD in 2025; YoY growth 36.1%; net margin -68.0%; ROE -52.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 8.2x
What contradicts it
- Interest coverage: -47.4x
- FCF yield: -5.3%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Electromedical & Electrotherapeutic Apparatus (SIC 3845) · same industry (4-digit SIC) · compared with 24 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| MDTMedtronic plc | 126.5 bn | 24.3 | 10.7% | 13.9% | +8.4% | −6% / +25% |
| LIVNLivaNova PLC | 5.2 bn | 27.8 | 15.4% | 12.8% | +10.7% | +48% / +110% |
| ITGRInteger Holdings Corporation | 4.3 bn | 42.5 | 6.0% | 5.7% | +8.0% | +75% / +45% |
| AXGNAxogen, Inc. | 3.1 bn | — | -10.3% | -12.0% | +20.2% | +79% / +684% |
| TMDXTransMedics Group, Inc. | 2.5 bn | 18.9 | 36.3% | 22.7% | +37.1% | −50% / −4% |
| BLFSBioLife Solutions, Inc. | 1.9 bn | 33.5 | 15.1% | 56.4% | +28.9% | unavailable / unavailable |
| CNMDConmed Corporation | 1.6 bn | 21.8 | 7.1% | 5.4% | +5.2% | +24% / −50% |
| CBLLCeriBell, Inc. | 1.1 bn | — | -52.5% | -68.0% | +36.1% | +151% / unavailable |
| INMDInMode Ltd. | 899.7 m | 9.9 | 13.5% | 25.3% | −6.2% | −0% / −40% |
| CVCapsoVision, Inc | 342.8 m | — | — | -214.7% | +15.3% | +23% / unavailable |
| ELMDElectromed, Inc. | 234.3 m | 21.5 | 23.3% | 15.3% | +15.3% | +5% / +172% |
| FOCLEdap Tms SA | 162.9 m | — | -321.7% | -49.1% | +1.6% | +81% / −17% |
| VANIVivani Medical, Inc. | 96.5 m | — | -220.4% | — | unavailable | −21% / +13% |
| STXSStereotaxis, Inc. | 95.9 m | — | -325.9% | -74.2% | +20.3% | −61% / −42% |
| NRXSNeuraxis, Inc. | 86.1 m | — | -139.8% | -144.4% | +32.9% | +147% / +117% |
| OMOutset Medical, Inc. | 83.5 m | — | -59.2% | -63.1% | +5.1% | −3% / −94% |
| ECORelectroCore, Inc. | 75.7 m | — | — | -40.0% | +27.2% | +66% / +49% |
| POCIPrecision Optics Corporation, Inc. | 53.1 m | — | -22.3% | -11.5% | +65.2% | +3% / −18% |
| NXLNexalin Technology, Inc. | 34.4 m | — | -240.3% | -4,139.4% | +78.8% | −95% / −87% |
| QTIQt Imaging Holdings, Inc. | 32.1 m | — | -2,125.0% | -77.3% | +287.9% | −64% / −99% |
| NUWENuwellis, Inc. | 19.2 m | — | — | -125.6% | −5.4% | −94% / −100% |
| IRIXIridex Corp | 12.6 m | — | -73.1% | -6.9% | unavailable | −26% / −72% |
| NDRAEndra Life Sciences Inc. | 7.4 m | — | -152.0% | — | unavailable | −16% / −100% |
| ITOCiTonic Holdings Ltd | — | — | -82.8% | -974.7% | +16.7% | −80% / unavailable |
| HYPRHyperfine, Inc. | 0 | — | -97.0% | -210.8% | +5.2% | −30% / −41% |
1- and 3-year price returns: for CBLL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 10 Aug 2026; since then the company filed 8-K (03 Nov 2026 · results), 10-Q (03 Nov 2026).
In brief
Ceribell is a medical technology company that develops a portable point-of-care EEG system with AI-powered algorithms for detecting seizures and delirium in intensive care and emergency settings. In the second quarter of 2026 the company reported 33% revenue growth and raised its fiscal 2026 revenue guidance to a range of 114 to 117 million USD 3.
SWOT
Strengths
- A portable platform that non-specialized staff can apply, backed by proprietary algorithms and an extensive base of peer-reviewed publications 1.
- Steady growth in active accounts and utilization within existing hospitals supports subscription revenue 3.
- A proprietary patent portfolio and multiple FDA clearances strengthen the competitive position 1.
Weaknesses
- A history of net losses and accumulated deficits, with operating expenses rising quickly.
- Dependence on sales of the Ceribell System with no substantial revenue diversification.
- Reliance on third-party manufacturers in Asia exposes the company to supply chain disruptions.
Opportunities
- Expansion into new indications such as stroke detection could open additional markets.
- If NTAP reimbursement for delirium monitoring takes effect, hospital adoption could accelerate.
- International expansion, particularly in Europe where the company holds a CE Mark, could add revenue.
Threats
- Staff resistance to new technology and loyalty to conventional EEG could slow adoption.
- Clinical studies reporting algorithm limitations could damage the brand's reputation.
- Changes in reimbursement or hospital budgets could reduce demand for new subscriptions.
Risks
- Persistent net losseshigh
The company has incurred losses since inception and expects future losses, which could require additional capital if revenue does not cover expenses.
- Dependence on hospital adoptionhigh
Revenue depends almost entirely on hospital use of the system, and customers can terminate subscriptions on short notice.
- International supply chainmedium
Headband assembly takes place in China and Vietnam, so tariffs or geopolitical tensions could disrupt production.
- Patent litigationmedium
The suit against Natus Medical and other disputes could generate large legal costs with uncertain outcomes.
- Regulation and reimbursementmedium
Changes in FDA requirements or CMS reimbursement could alter market access and revenue.
Investment thesis
What would need to be true (bull case)
- Rapid growth in accounts and utilization, combined with raised guidance, suggests adoption could continue over several years.
- High gross margins and a growing set of FDA clearances could support long-term revenue growth.
- If new indications and international markets develop, the company could extend beyond its current U.S. hospital base.
What would break the thesis
- Net losses and rapidly rising expenses could prolong the path to profitability and reduce cash reserves.
- Dependence on a single product and on hospitals keeping subscriptions could expose revenue to fluctuations.
- Second-quarter margin benefited from one-time tariff refunds, so future margins could be lower.
What to watch
- Progress of fiscal 2026 revenue guidance against the 114 to 117 million USD rangeQ3 2026
- Number of active accounts and the pace of new account additionsQ3 2026
- Effect of the delirium NTAP reimbursement effective October 20262027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 10 Aug 2026; since then the company filed 8-K (03 Nov 2026 · results), 10-Q (03 Nov 2026).
The business
Ceribell, Inc. is a medical technology company focused on diagnosing and managing patients with serious neurological conditions through the Ceribell System, a portable EEG platform with disposable headbands, a rechargeable recorder and proprietary AI-based detection algorithms 1. It earns revenue from two recurring sources: sales of single-use Wearables and monthly subscription fees paid by hospitals for Clarity, recorders and the portal 1. As of June 30, 2026 the system had been adopted by more than 700 hospitals 2.
Segments
New indications
Beyond seizure detection, the company received FDA clearance for delirium monitoring and a Breakthrough Device Designation for a large vessel occlusion stroke solution still in development 1.
Market context
The company estimates that approximately 6,000 acute care facilities in the United States could benefit from the system, and that its annual addressable market has grown to over 3.5 billion USD after the delirium indication 1. According to the company, over three million acute care patients should be monitored with EEG each year because of high seizure risk 1.
Trends
- Rising hospital adoptiontailwind
The number of active accounts kept growing and utilization within existing accounts increased even during the seasonally lower ICU census of summer, which could support revenue growth if the pattern holds.
- New FDA clearancestailwind
Clearances for new algorithms and the next-generation hardware platform could open additional indications and application areas, provided reimbursement follows.
- Tariffs and supply chainmixed
Manufacturing depends on contract manufacturers in China and Vietnam, and tariffs could weigh on margins; refunds of previously paid tariffs gave a one-time benefit to the second quarter of 2026.
- Pressure on operating expensesheadwind
Sales, marketing and general expenses are growing faster than revenue and the net loss persists, which could prolong the time to profitability.
Competitive position
The main alternative named in the sources is conventional EEG, used for decades, which requires specialized technicians and neurologists and is the standard hospitals already know 1. The filings also point to intense competition in the industry and to a patent infringement suit against Natus Medical Incorporated filed in July 2025 3.
- Conventional EEG in neurophysiology laboratories
Traditional systems require specialized technicians and neurologist interpretation, which creates delays in acute care.
- Natus Medical Incorporated
Company against which Ceribell filed a patent infringement action in July 2025, indicating direct rivalry in the EEG market.
- Existing EEG equipment vendors with hospital relationships
Established EEG suppliers with entrenched hospital ties may present a barrier to winning new accounts.
- Other neurological monitoring solutions for intensive care
Other brain monitoring systems may compete for hospital budgets earmarked for monitoring critically ill patients.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report03 Nov 2026
- Current report03 Nov 2026Results of operations · Financial statements and exhibits
- Quarterly report10 Aug 2026
- Current report10 Aug 2026Results of operations · Financial statements and exhibits
- Current report30 Jul 2026Departure or appointment of officers
- Current report02 Jun 2026Shareholder vote
- Quarterly report11 May 2026
- Current report11 May 2026Results of operations · Financial statements and exhibits
- Proxy statement20 Apr 2026
- Annual report24 Feb 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Ceribell, Inc. · 24 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Ceribell, Inc. · 10 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Ceribell, Inc. · 10 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.